Cunningham Kent Douglas 4

What Happened

• Kent Cunningham, CEO of SRx Health Solutions (SRXH), reported multiple acquisitions classified as awards/grants and derivative acquisitions between 2024-06-26 and 2026-03-16. The transactions include outright grants/awards and acquisitions tied to derivative securities (e.g., option/warrant-related transactions), with aggregate reported value of about $735,009.
• Notable pieces: large grants such as 200,000 shares at $0.39 ($78,000), 231,193 shares at $0.40 ($93,402), and several other awards at prices ranging from $0.32 to $5.00. A small number of shares (63) were acquired at $800.00 each (reported value $50,400).

Key Details

• Transactions (date — shares @ price = value; “derivative” where indicated):
  • 2025-12-03 — 200,000 @ $0.39 = $78,000
  • 2025-09-26 — 44,464 @ $0.33 = $14,673
  • 2025-08-25 — 231,193 @ $0.40 = $93,402
  • 2025-04-25 — 84,906 @ $1.59 = $135,001
  • 2025-04-24 — 71,770 @ $2.09 = $149,999
  • 2024-06-26 — 22,727 @ $4.17 = $94,772
  • 2026-03-16 — 63 @ $800.00 = $50,400
  • 2024-06-26 — 8,000 @ $5.00 = $40,000 (derivative)
  • 2026-03-16 — 247,522 @ $0.32 = $78,762 (derivative)
• Total reported value ≈ $735,009 across the listed transactions.
• Filing date: 2026-04-03. Period of report listed as 2024-06-24. The Form 4 should be reviewed for any timeliness flag if you are concerned about late reporting.
• Shares beneficially owned after these transactions: not disclosed in the summary data provided. Check the Form 4 for the “Amount Beneficially Owned” field.
• No 10b5-1 plan, tax-withholding, or other footnotes were included in the summary data provided here; review the Form 4 for any detailed footnotes.

Context

• These are acquisitions via awards/grants and derivative-related acquisitions; awards are typically compensation-related (not the same as open-market purchases) and can reflect standard executive pay rather than a personal cash purchase or a market-taking bullish bet.
• Derivative entries usually reflect option/warrant-related transactions or exercises — the Form 4 will clarify whether options were exercised or other derivative actions occurred.
• No sales were reported here; immediate sales (cashless exercises) are not indicated in the summary. Review the full Form 4 for any additional clarifying details before drawing conclusions.